×
AllNewsImages Maps Videos Books
Search tools

Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific, joining red-hot race with BioNTech, Merck

Fierce Biotech
Pfizer made a splashy entrance late Monday, revealing it is paying $1.25 billion upfront and committing up to $4.8 billion in milestones for ex-...
1 month ago

Pfizer buys into PD-1/VEGF competition with 3SBio deal

BioPharma Dive
Pfizer buys into PD-1/VEGF competition with 3SBio deal. Pfizer will pay China's 3SBio $1.25 billion up front to access a cancer drug that works...
1 month ago

Pfizer Enters into Exclusive Licensing Agreement with 3SBio

Business Wire
Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK), a leading Chinese...
2 months ago

Pfizer licenses cancer bispecific antibody from Chinese developer 3SBio in $1.25 billion bid

BioProcess International
Pfizer has entered an exclusive licensing agreement with Chinese biologic developer 3SBio for the development, manufacturing, and commercialization of...
1 month ago

Pfizer in deal with China's 3SBio to license cancer drug candidate, take equity stake

Reuters
US drugmaker Pfizer (PFE.N) said it would license an experimental cancer treatment from China's 3SBio Inc (1530.HK), paying $1.25 billion upfront.
2 months ago

While institutions invested in 3SBio Inc. (HKG:1530) benefited from last week's 16% gain, individual investors stood to gain the most

Simply Wall Street
Key Insights 3SBio's significant individual investors ownership suggests that the key decisions are influenced by...
4 days ago

Pfizer strikes $1.25 billion licensing deal with Chinese biopharma 3SBIO

Medical Marketing and Media
Pfizer strikes $1.25 billion licensing deal with Chinese biopharma 3SBIO. The pharma giant entered an exclusive agreement with the Chinese...
1 month ago

Pfizer signs global licensing deal with 3SBio for bispecific antibody

Pharmaceutical Technology
Pfizer signs global licensing deal with 3SBio for bispecific antibody. Pfizer will pay $1.25 upfront, and 3SBio could earn up to $4.8bn in...
1 month ago

Chris Boshoff: Pfizer Enters Licensing Agreement with 3SBio for Next-Gen Bispecific Antibody

Oncodaily
Pfizer has entered into an exclusive licensing agreement with 3SBio Inc., focused on the global, ex-China, development and commercialization of a next-...
1 month ago

Pfizer Signs Experimental Drug Licensing Agreement With 3SBio

Yahoo Finance
In This Article: ... Pharmaceutical giant Pfizer Inc. PFE has signed a significant licensing agreement with China's 3SBio Inc. for an experimental...
1 month ago